Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis

被引：1

作者：

Colombel, Jean-Frederic ^{[1
]}

Sandborn, William ^{[2
]}

Wolf, Doug ^{[3
]}

Panaccione, Remo ^{[4
]}

Lazar, Andreas ^{[5
]}

Kron, Martina ^{[5
]}

Robinson, Anne ^{[6
]}

Thakkar, Roopal ^{[6
]}

机构：

[1] CHRU, Hop Huriez, Lille, Nord, France

[2] Univ Calif San Diego, La Jolla, CA 92093 USA

[3] Atlanta Gastroenterol Associates, Atlanta, GA USA

[4] Univ Calgary, Calgary, AB, Canada

[5] Abbott GmbH & Co KG, Ludwigshafen, Germany

[6] Abbott Labs, Abbott Pk, IL 60064 USA

来源：

INFLAMMATORY BOWEL DISEASES | 2012年 / 18卷

关键词：

D O I：

10.1097/00054725-201212001-00052

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

下载

页码：S20 / S21

页数：2

共 50 条

[1] Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis
Colombel, Jean-Frederic
Sandborn, William
Wolf, Douglas
Panaccione, Remo
Lazar, Andreas
Kron, Martina
Robinson, Anne
Thakkar, Roopal
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S652 - S652
[2] Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis
Kim, Jae Hyun
Cheon, Jae Hee
GUT AND LIVER, 2016, 10 (02) : 162 - 163
[3] Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
Yasuo Suzuki
Satoshi Motoya
Hiroyuki Hanai
Takayuki Matsumoto
Toshifumi Hibi
Anne M. Robinson
Nael M. Mostafa
Jingdong Chao
Vipin Arora
Anne Camez
Roopal B. Thakkar
Mamoru Watanabe
Journal of Gastroenterology, 2014, 49 : 283 - 294
[4] Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
Suzuki, Yasuo
Motoya, Satoshi
Hanai, Hiroyuki
Matsumoto, Takayuki
Hibi, Toshifumi
Robinson, Anne M.
Mostafa, Nael M.
Chao, Jingdong
Arora, Vipin
Camez, Anne
Thakkar, Roopal B.
Watanabe, Mamoru
JOURNAL OF GASTROENTEROLOGY, 2014, 49 (02) : 283 - 294
[5] Long-term use of ozanimod in patients with moderately to severely active Ulcerative Colitis
Danese, S.
Colombel, J. F.
Ponich, T.
Jovanovic, I.
Bossuyt, P.
Longman, R.
Alekseeva, O.
Petersen, A.
Chitkara, D.
Marta, C.
Charles, L.
Rubin, D. T.
Afzali, A.
Loftus, E. V.
Wolf, D. C.
JOURNAL OF CROHNS & COLITIS, 2022, 16 : I093 - I094
[6] LONG-TERM USE OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Wolf, Douglas C.
Colombel, Jean Frederic
Ponich, Terry P.
Jovanovic, Igor
Bossuyt, Peter
Longman, Randy
Alekseeva, Olga
Petersen, AnnKatrin
Chitkara, Denesh
Marta, Cecilia
Charles, Lorna
Rubin, David T.
Afzali, Anita
Loftus, Edward V.
Danese, Silvio
GASTROENTEROLOGY, 2022, 162 (07) : S969 - S969
[7] Long-term use of ozanimod in patients with moderately to severely active ulcerative colitis
Danese, S.
Colombel, J-F
Ponich, T.
Jovanovic, I.
Bossuyt, P.
Longman, R.
Alekseeva, O.
Petersen, A. K.
Marta, C.
Charles, L.
Sparrow, M.
Rubin, D. T.
Afzali, A.
Loftus, E. V., Jr.
Wolf, D. C.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 125 - 126
[8] COST-EFFECTIVENESS OF ADALIMUMAB FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN CANADA
Ghosh, S.
Desjardins, O.
Skup, M.
Wang, S.
Yang, M.
Yang, H.
Qi, C.
Bao, Y.
Chao, J.
VALUE IN HEALTH, 2014, 17 (03) : A37 - A37
[9] Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis
J. Ignacio Fernández-Blanco
Guillermo Fernández-Díaz
Carlos Cara
María I. Vera
David Olivares
Carlos Taxonera
Digestive Diseases and Sciences, 2018, 63 : 731 - 737
[10] Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis
Ignacio Fernandez-Blanco, J.
Fernandez-Diaz, Guillermo
Cara, Carlos
Vera, Maria I.
Olivares, David
Taxonera, Carlos
DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (03) : 731 - 737

← 1 2 3 4 5 →